EUVIMEDEUVIMED entdecken
Crossref

Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods

Ogochukwu Ukamaka Amaeze, Oyetunde, Olubukola O., Moshood Olusola Akinleye, Oluwole, David O.

Afrischolar Discovery · 23.11.2023

DOI: 10.60787/wapcp-26-2-95 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Afrischolar Discovery, erschienen am 23.11.2023. Verfasst von Ogochukwu Ukamaka Amaeze und 5 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Generic medicines must be therapeutic equivalents with the innovator brand before substitution is appropriate.

Objective

This study was carried out to evaluate the in vitro equivalence of valsartan (a BCS Class III drug) tablets under Biowaiver conditions.

Methods

Physicochemical parameters were assessed in accordance with BP and USP specifications. Therapeutic equivalence of the innovator and commonest generic brands were investigated using in vitro methods.

Results

The tested valsartan brands investigated complied with Compendia specifications for tablets. Valsartan tablets were not very rapidly dissolving as per WHO Biowaiver testing specifications. Both test and reference products were poorly soluble in acidic medium (pH 1.2), while 85% of the drug was released at 15 minutes in pH 6.8. Dissolution profiles of the test and innovator brands were similar at pH 1.2 and 6.8 (f2: 65 and 69 respectively), and dissimilar at pH 4.5 (f2: 30). The generic valsartan tablets evaluated in this study showed pharmaceutical equivalence with the innovator brand. The test and reference products were not however very rapidly dissolving as required for BCS Class III drugs.

Conclusion

The valsartan tablet brands tested did not meet WHO BCS-based biowaiver conditions. In vivo bioequivalence studies are recommended to ascertain therapeutic equivalence and interchangeability.

Schlagwörter

valsartanbiowaivergeneric substitutiontherapeutic equivalencepharmaceutical equivalencedissolution testingBCS class III drugsin vitro drug releasegeneric tabletsphysicochemical parameters

Zitieren

APA

Amaeze, O. U., Oyetunde, O., O., Akinleye, M. O., Oluwole, & O., D. (2023). Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods. Afrischolar Discovery. https://doi.org/10.60787/wapcp-26-2-95

Vancouver

Amaeze OU, Oyetunde, O. O, Akinleye MO, Oluwole, O. D. Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods. Afrischolar Discovery. 2023. doi:10.60787/wapcp-26-2-95

BibTeX
@article{Amaeze2023,
  author = {Amaeze, Ogochukwu Ukamaka and Oyetunde and O., Olubukola and Akinleye, Moshood Olusola and Oluwole and O., David},
  title = {Biowaiver assessment of some commercially available brands of valsartan tablets using in vitro methods},
  journal = {Afrischolar Discovery},
  year = {2023},
  doi = {10.60787/wapcp-26-2-95}
}
Kostenlos starten →